BVMF
FLRY3
Market cap2.85bUSD
Oct 08, Last price
26.35BRL
1D
2.29%
1Q
60.48%
Jan 2017
49.46%
IPO
72.90%
Name
Fleury SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fleury S.A., a Brazilian healthcare provider, along with its subsidiaries, delivers a broad spectrum of medical services. These offerings span diagnostics, various treatments, clinical analysis, health management, general medical care, orthopedics, and ophthalmology. The company organizes its operations into three primary segments: Diagnostic Medicine, Integrated Medicine, and Dental. Its service portfolio includes laboratory and imaging examinations, comprehensive diagnostic information, health check-ups, specialized reference laboratory functions, genomic testing, day clinic facilities, infusion centers, and dental imaging and radiology. Additionally, Fleury provides Saúde I, a digital health platform that facilitates teleconsultations, remote medical advice, online diagnostic exams, and virtual procedures. It further extends its services to corporate clients with tailored solutions, offers in-person primary care, and supports medical professionals through digital office tools and ongoing medical education. Established in 1926 and headquartered in São Paulo, Brazil, the company operates an extensive network comprising 284 outpatient service centers and 31 hospital-based units, many of which are known under brands like Labs a+, Felippe Mattoso, Lafe, Fleury, a+SP, CIP, Moacir Cunha, Vita, inlab, Weinmann, Serdil, Diagmax, IRN / CPC, Diagnosis a+, a+BA, Pretti, and Bioclinic.
Key people
Marcio Mendes
Chairman of the Board · since 2019
Fernando Alberto
Vice Chairman of the Board · since 2018
Jose de Almeida Filippo
Chief Financial and Investor Relations Officer, Member of the Executive Board · since 2021
Patricia Bertoncello
Member of the Executive Board, Service Units Officer · since 2024
Roberto Meirelles
Member of the Executive Board, L2L and Operations Support Officer · since 2023
Edgar Rizzatti
Member of the Executive Board, Medical, Technical and Process Officer · since 2021
Jeane Tsutsui
Chief Executive Officer, Member of the Executive Board · since 2021
Luiz Cappi
Director · since 2019
Rui de Barros Maciel
Director · since 2019
Director · since 2017
Director · since 2020
Marcio de Paula Ricardo
Independent Director · since 2024
Victor Pardini
Independent Director · since 2023
Regina Pardini
Independent Director · since 2023
Independent Director · since 2021
Valuation
Title BRL in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||